Sensitivity of secondary acute myeloid leukemia relapsing after allogeneic bone marrow transplantation to immunotherapy with interferon-alpha 2b

Bone Marrow Transplantation
S SinghalJ Mehta

Abstract

A patient with acute myeloid leukemia secondary to therapy of choriocarcinoma underwent T cell non-depleted allogeneic bone marrow transplantation from an unrelated donor in first untreated relapse. Persistent/relapsed leukemia 4 months after transplantation did not respond to cessation of cyclosporine. Due to logistic difficulties in obtaining donor leukocytes, she was treated with interleukin-2 and interferon-alpha 2b. Although the interleukin could be administered for a short period only, the interferon was continued for 4 months. Interferon was stopped when limited chronic graft-versus-host disease developed, but was followed by extramedullary and early marrow relapse. Reinstitution of interferon resulted in the development of scleroderma-like extensive chronic GVHD and remission. Interferon was given for 5 months. GVHD improved slowly with treatment, but scleroderma-like changes still persist. The patient is alive with no evidence of disease and a Karnofsky score of 90% 41 months after relapse and 26 months after stopping cyclosporine. We conclude that cytokines alone may occasionally result in a durable response of acute leukemia relapsing after allografting, and should be considered in patients with a low tumor burden if...Continue Reading

Citations

Oct 27, 2009·Bone Marrow Transplantation·B N SavaniK Rezvani
Jan 29, 2011·Leukemia·S AnguilleE L J M Smits
Oct 27, 2006·Leukemia & Lymphoma·Isabel Cunningham
Jun 28, 2015·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Xiao-Dong MoXiao-Jun Huang
Jan 16, 2007·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Martha L ArellanoEdmund K Waller
May 18, 2001·Best Practice & Research. Clinical Haematology·P B LangmuirB J Lange
May 10, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hillard M LazarusGeoffrey P Herzig
Oct 14, 2004·Springer Seminars in Immunopathology·Norbert-Claude Gorin
Aug 16, 2003·Blood·H Joachim DeegFrederick R Appelbaum
Nov 9, 2006·Blood·Roland MeiselUNKNOWN Impfung von Kindern nach allogener Stammzelltransplantation (IKAST) Study Group
Jul 13, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Koen van BesienW Stock
Feb 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anthony S SteinStephen J Forman

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.